ATHERSYS INC (ATHX)       0.566  -0.04 (-7.03%)

0.566  -0.04 (-7.03%)

US04744L2051 - Common Stock - After market: 0.57 +0 (+0.71%)

ATHERSYS INC0.566

NASDAQ:ATHX (12/6/2022, 7:22:32 PM)-0.04 (-7.03%)

After market: 0.57 +0 (+0.71%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS Sector Health Care
GICS Industry Biotechnology
Chartmill FA Rating
Valuation Growth
Profitability Health
Dividend
Overview
Earnings (Last) 11-14 2022-11-14/amc Earnings (Next) 03-13 2023-03-13
Ins Owners 10.52% Inst Owners 5.18%
Market Cap 9.85M Shares 17.40M
PE N/A Fwd PE N/A
Dividend Yield N/A Analysts 40
IPO 04-23 2007-04-23

Stock Screener Links

Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Growth Stock Screener

Find more growth stocks the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

ATHX Daily chart

Company Profile

Athersys, Inc. engages in the discovery and development of therapies designed to extend and enhance to quality of human life. The company is headquartered in Cleveland, Ohio and currently employs 104 full-time employees. The company went IPO on 2007-04-23. The company is engaged in the discovery and development of therapeutic product candidates. Its MultiStem (invimestrocel) cell therapy, which is an allogeneic stem cell product candidate, is its lead platform product and is in late-stage clinical development. The MultiStem cell therapy includes treatment of critical care indications, neurological conditions, inflammatory and immune disorders, certain pulmonary conditions, cardiovascular disease, and other conditions. MultiStem cell therapy is manufactured from human stem cells obtained from adult bone marrow and these cells may alternatively be obtained from other tissue sources. The company is conducting a Phase III clinical trial of MultiStem cell therapy for the treatment of ischemic stroke, referred to as MASTERS-2. The company is enrolling a pivotal Phase II/III clinical trial evaluating MultiStem cell therapy in COVID-19 induced and other pathogen-induced acute respiratory distress syndrome (ARDS) patients.

Company Info

ATHERSYS INC

3201 Carnegie Ave

CLEVELAND OHIO 44115

P: 12164319900.0

CEO: William Lehmann Jr.

Employees: 104

Website: http://www.athersys.com/

ATHX Twits

Here you can normally see the latest stock twits on ATHX, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example